top up opportunity - technical counsel. , page-8

Hi all,
classic case of people not understanding PRR and its product.
Happened 3 times over last few years with big drops of over 50%.
The product is different from dendreon , targeting a different organ and a different sex although the model for FDA approval is similar.

PRR is two years off trial results and people panicking because dendreon has a poor sales forecast.
PRR will have a run up closer to trial results irrespective. This one is for keeps , atleast for me as risk reward ratio is too tempting to ignore.
I agree with many chartists that indicated that the short term trend is down. However i look usually for the 13, 50 MA and 200MA for my decisions on 1 year and 3 year chart as my investment time frame is long.
good luck all.
my call is in retrospect the capitulation will be seen as a buying opp . buy when people are fearful , sell when people are greedy ( easier said than done)